Creating a new generation of small molecule protease inhibitors

Investors Overview

Corporate Profile

KalVista is a pharmaceutical company focused on the discovery, development and commercialization of small molecule protease inhibitors as new treatments for diseases with significant unmet needs.

NASDAQ | KALV (Common Stock)
$9.16-0.06 (0.65%)
Stock chart for: KALV.O. Currently trading at $9.16 with a 52 week high of $15.80 and a 52 week low of $5.48.
Data provided by Nasdaq. Minimum 15 minutes delayed.
View Attributions and Sources

Recent News

April 18, 2018KalVista Pharmaceuticals to Present Data at The Association for Research in Vision and Ophthalmology (ARVO) 2018 Annual Meeting

March 16, 2018KalVista Pharmaceuticals Reports Fiscal Third Quarter Results

March 05, 2018KalVista Pharmaceuticals to Present at 30th Annual ROTH Conference

More News

Featured Presentations

Download Documentation Corporate Presentation